PW MEDTECH (01358): Sichuan Ruijian Medical's net profit attributable to the parent company in 2025 is expected to be approximately 151 million yuan, a year-on-year increase of 17.99%.

18:29 12/02/2026

Puhua and Shun (01358) released the performance of its subsidiary Sichuan Ruijian Medical Technology Co., Ltd. (Sichuan Ruijian Medical) in 2025, with a revenue of approximately 615 million yuan, a year-on-year increase of 27.22%; the net profit attributable to Sichuan Ruijian Medical shareholders is approximately 151 million yuan, a year-on-year increase of 17.99%.

PW MEDTECH (01358) announced the 2025 performance of its subsidiary Sichuan Ruijian Medical Technology Co., Ltd. (Sichuan Ruijian Medical), with revenue of approximately 615 million yuan, a year-on-year increase of 27.22%; net profit attributable to shareholders of Sichuan Ruijian Medical is approximately 151 million yuan, a year-on-year increase of 17.99%.

Zhejiang Hisun Biomaterials (688203.SH): Sinopec Capital plans to reduce its shareholding by no more than 1%

MOKINGRAN (02585) completes the full circulation of H shares.

SHOUHUI GROUP (02621) spent about 20,900 Hong Kong dollars to repurchase 6,000 shares on February 12th.

Zhejiang Hisun Biomaterials (688203.SH): Sinopec Capital plans to reduce its shareholding by no more than 1%

MOKINGRAN (02585) completes the full circulation of H shares.

SHOUHUI GROUP (02621) spent about 20,900 Hong Kong dollars to repurchase 6,000 shares on February 12th.